Unknown

Dataset Information

0

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.


ABSTRACT: NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)-rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis. To identify liver-regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F ( APOF ) expression showed the fourth-strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral-mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)-TG secretion and hepatic lipoprotein remnant clearance, associated a ~25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo , and reduced hepatocyte VLDL uptake by ~15% in vitro . Transcriptomic analysis of APOF -overexpressing mouse livers revealed a gene signature related to enhanced ApoB-lipoprotein clearance, including increased expression of Ldlr and Lrp1 , among others. These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL-TG secretion and hepatic lipoprotein remnant particle clearance.

SUBMITTER: Deprince A 

PROVIDER: S-EPMC10026963 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.

Deprince Audrey A   Hennuyer Nathalie N   Kooijman Sander S   Pronk Amanda C M ACM   Baugé Eric E   Lienard Viktor V   Verrijken An A   Dirinck Eveline E   Vonghia Luisa L   Woitrain Eloïse E   Kloosterhuis Niels J NJ   Marez Eléonore E   Jacquemain Pauline P   Wolters Justina C JC   Lalloyer Fanny F   Eberlé Delphine D   Quemener Sandrine S   Vallez Emmanuelle E   Tailleux Anne A   Kouach Mostafa M   Goossens Jean-Francois JF   Raverdy Violeta V   Derudas Bruno B   Kuivenhoven Jan Albert JA   Croyal Mikaël M   van de Sluis Bart B   Francque Sven S   Pattou François F   Rensen Patrick C N PCN   Staels Bart B   Haas Joel T JT  

Hepatology (Baltimore, Md.) 20220715 4


<h4>Background</h4>NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)-rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the sett  ...[more]

Similar Datasets

| S-EPMC3750732 | biostudies-literature
| S-EPMC4509984 | biostudies-literature
| S-EPMC6662658 | biostudies-literature
| S-EPMC3351826 | biostudies-literature
| S-EPMC4767000 | biostudies-literature
2013-09-15 | E-GEOD-32515 | biostudies-arrayexpress
| S-EPMC5806881 | biostudies-literature
2013-09-15 | GSE32515 | GEO
| S-EPMC5027931 | biostudies-literature
| S-EPMC6071769 | biostudies-literature